Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of surgical oncologist Dr Yanghee Woo to its scientific advisory board.
Dr Woo is an Associate Professor of Surgery at the US-based City of Hope medical centre. She is a recognised surgeon-scientist with clinical expertise in robotic surgery and gastric cancer.
Dr Woo is also currently researching gastric cancer inception and viral oncolytic therapy based on the CF33-platform. She is part of the team that created a chimeric orthopoxvirus, CF33-hNIS-antiPDL1, that has exhibited strong potential in targeting solid tumours and the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC).
Dr Woo has previously held various positions at Columbia University Medical Center's Pancreas Center where she was Assistant Professor of Surgery and later director of the Center for Global Excellence in Gastric Cancer Care.
The company also announced the resignation of chief medical officer Dr Steven Cha due to family reasons.
Managing director and CEO Leslie Chong said, "Imugene is proud to have yet another world-class physician and scientist join our Scientific Advisory Board. Dr Woo will enhance the strength of our already impressive medical and scientific team and we look forward to leveraging her expertise as we develop our clinical pipeline.
"We appreciate the contributions Dr Cha has made to Imugene over the last several months and wish him the very best in his future endeavours."
